ATYR1940 EARLY ONSET FSHD (003) TRIAL: PHASE 1B/2

In the fourth quarter of 2015, we initiated a multinational, multi-center Phase 1b/2 clinical trial of ATYR1940 in patients with early onset FSHD. This international Phase 1b/2 clinical trial is an open-label, intra-patient dose escalation study designed to assess the safety, tolerability, immunogenicity and biological activity of ATYR1940 at weekly doses of 0.3, 1.0 and 3.0 mg/kg to patients with early onset FSHD.

Study protocol is to enroll 8 patients between the ages of 16 and 25.

We announced final results in the second quarter of 2017.

Data Release
 
Clinicaltrials.gov

© 2007 - 2018   aTyr Pharma.   Legal   Privacy Policy